Evidence map›Paper›PMID 32911782›Full record

ArticleInternational journal of molecular sciences2020

Cerebral Vasodilator Property of Poly(ADP-Ribose) Polymerase Inhibitor (PJ34) in the Neonatal and Adult Mouse Is Mediated by the Nitric Oxide Pathway.

Philippe Bonnin, Christiane Charriaut-Marlangue, Julien Pansiot, Alexandre Boutigny, Jean-Marie Launay, Valérie C Besson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Philippe BonninU1275, INSERM, F-75010, Physiologie Clinique-Explorations Fonctionnelles, Hopital Lariboisiere, Université de Paris, 2, Rue Ambroise Pare, 75010 Paris, France.ORCID 0000-0003-3184-3740
Christiane Charriaut-MarlangueU1141 NeuroDiderot, INSERM, Hôpital Robert Debré, Université de Paris, 48 Boulevard Sérurier, 75019 Paris, France.ORCID 0000-0002-9632-5453
Julien PansiotU1141 NeuroDiderot, INSERM, Hôpital Robert Debré, Université de Paris, 48 Boulevard Sérurier, 75019 Paris, France.
Alexandre BoutignyU1275, INSERM, F-75010, Physiologie Clinique-Explorations Fonctionnelles, Hopital Lariboisiere, Université de Paris, 2, Rue Ambroise Pare, 75010 Paris, France.
Jean-Marie LaunayUMR-S942-Biomarqueurs Cardiovasculaires, Hopital Lariboisiere, Université de Paris, 2, Rue Ambroise Pare, 75010 Paris, France.
Valérie C BessonUMR-S1144-Optimisation Thérapeutique en Neuropsychopharmacologie, Faculté de Pharmacie de Paris, Université de Paris, 4 Avenue de l'Observatoire, 75006 Paris, France.ORCID 0000-0002-1491-2380
Inserm · FRUniversité Paris Cité · FR

Funding

Fondation pour la Recherche sur les AVC sous l'égide de la FRM FRAVC170922006
6 · The paper itself

Abstract

The poly(ADP-ribose) polymerase (PARP) inhibitor PJ34 has been reported to improve endothelial dysfunction in the peripheral system. We addressed the role of PJ34 on the vascular tone and vasoreactivity during development in the mouse brain. Blood flows were measured in the basilar trunk using ultrasonography. Cerebral vasoreactivity or vasodilation reserve was estimated as a percentage increase in mean blood flow velocities (mBFV) recorded under normoxia-hypercapnia in control and after PJ34 administration. Non-selective and selective eNOS and nNOS inhibitors were used to evaluate the role of NO-pathway into the hemodynamic effects of PJ34. PJ34 increased mBFVs from 15.8 ± 1.6 to 19.1 ± 1.9 cm/s (

Indexed as

Age FactorsAnimalsAnimals, NewbornBrainCerebrovascular CirculationDisease Models, AnimalMaleMiceMice, Inbred C57BLNitric OxideNitric Oxide SynthasePhenanthrenesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesVasodilator AgentsNitric OxideNitric Oxide SynthaseN-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloridePhenanthrenesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesVasodilator Agentsarterial dilationbraincerebral blood flowcerebral vasoreactivitymouseno synthase

Identifiers

PMID32911782
PMCPMC7555622
OpenAlexW3083957999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.